Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SA

Relief Therapeutics Holding SA / Key word(s): AGMEGM Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SA 01-Jun-2022 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SA Geneva, Switzerland, June 1, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) ("Relief" or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced that, at its Annual General Meeting ("AGM") of shareholders held on Tuesday, May 31, 2022, the proposed resolutions described in the AGM invitation and detailed below were approved by more than 85 percent of the represented votes.

1. Approval of the Annual Report, Statutory Financial Statements and Consolidated Financial Statements for the year 2021

The AGM approved the Annual Report, the Statutory Financial Statements and the Consolidated Financial Statements for the year 2021.

2. Appropriation of Results

The AGM approved to carry forward the loss for the year 2021 of CHF 29'553'450, thereby bringing the loss carried forward from CHF 157'935'435 to CHF 187'488'885.

3. Discharge of the Board of Directors and the Executive Committee

The AGM granted discharge to each and all members of the Board of Directors, still active or having resigned, and of the Executive Committee for their activities in the financial year 2021.

4. Increase of the Authorized Share Capital

The AGM approved to maintain an authorized share capital of around but not more than 50% of the ordinary share capital and, therefore, to increase the amount of the existing authorized share capital from CHF 6'564'970.92 to CHF 22'000'000.00.

5. Votes on the compensation of the members of the Board of Directors and of the Executive Committee

5.1. Binding vote on the total compensation of the members of the Board of Directors for the period from the Annual General Meeting 2022 until the Annual General Meeting 2023